Fulcrum Therapeutics Stock Probability of Future Stock Price Finishing Over 7.64
| FULC Stock | USD 7.64 0.06 0.78% |
Closest to current price Fulcrum long CALL Option Payoff at Expiration
Fulcrum |
Fulcrum Therapeutics Target Price Odds to finish over 7.64
The tendency of Fulcrum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.64 | 90 days | 7.64 | about 80.4 |
Based on a normal probability distribution, the odds of Fulcrum Therapeutics to move above the current price in 90 days from now is about 80.4 (This Fulcrum Therapeutics probability density function shows the probability of Fulcrum Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Fulcrum Therapeutics has a beta of 0.52. This usually indicates as returns on the market go up, Fulcrum Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Fulcrum Therapeutics will be expected to be much smaller as well. Additionally Fulcrum Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite. Fulcrum Therapeutics Price Density |
| Price |
Predictive Modules for Fulcrum Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fulcrum Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Fulcrum Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Fulcrum Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Fulcrum Therapeutics is not an exception. The market had few large corrections towards the Fulcrum Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fulcrum Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fulcrum Therapeutics within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | -0.29 | |
β | Beta against NYSE Composite | 0.52 | |
σ | Overall volatility | 1.46 | |
Ir | Information ratio | -0.09 |
Fulcrum Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fulcrum Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fulcrum Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Cantor Fitzgerald eyes Fulcrum Therapeutics stock, anticipates positive Phase 3 data |
Fulcrum Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fulcrum Stock often depends not only on the future outlook of the current and potential Fulcrum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fulcrum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 61.3 M | |
| Cash And Short Term Investments | 236.2 M |
Fulcrum Therapeutics Technical Analysis
Fulcrum Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Fulcrum Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Fulcrum Therapeutics. In general, you should focus on analyzing Fulcrum Stock price patterns and their correlations with different microeconomic environments and drivers.
Fulcrum Therapeutics Predictive Forecast Models
Fulcrum Therapeutics' time-series forecasting models is one of many Fulcrum Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Fulcrum Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Fulcrum Therapeutics
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Cantor Fitzgerald eyes Fulcrum Therapeutics stock, anticipates positive Phase 3 data |
Check out Fulcrum Therapeutics Backtesting, Fulcrum Therapeutics Valuation, Fulcrum Therapeutics Correlation, Fulcrum Therapeutics Hype Analysis, Fulcrum Therapeutics Volatility, Fulcrum Therapeutics History as well as Fulcrum Therapeutics Performance. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.